The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma

Simple item page
dc.contributor.authorTwycross, S. H.en_ZA
dc.contributor.authorBurger, Henrietteen_ZA
dc.contributor.authorHolness, Jen L.en_ZA
dc.date.accessioned2021-07-07T05:38:11Z
dc.date.available2021-07-07T05:38:11Z
dc.date.issued2019
dc.descriptionCITATION: Twycross, S. H., Burger, H. & Holness, J. 2019. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma. South African Journal of Surgery, 57(3):44-49, doi:10.17159/2078-5151/2019/v57n3a2832.
dc.descriptionThe original publication is available at http://www.scielo.org.za
dc.description.abstractBACKGROUND: Accurate pre-operative staging and correct surgical selection of patients with malignant melanoma reduces unnecessary morbidity and mortality, improves distant control and may improve survival. 18F-fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18F-FDG PET-CT) has been shown to be useful in exclusion of metastatic sites and aids in surgical planning in stage III and potentially resectable stage IV disease. The primary objective of the study was to determine whether the use of PET-CT alters the initial staging and management of patients with advanced and recurrent melanoma METHODS: Retrospective analysis of clinical records of patients with malignant melanoma referred for staging PET-CT over a three-year period at our institution was performed. Pre- and post-PET-CT stage was recorded and a descriptive analysis was done to determine whether PET-CT resulted in a change in stage grouping and whether this change effected a change in clinical management RESULTS: A change in stage grouping occurred in 21/39 (53.8%) of patients, 76.2% of which were up-staged and 23.8% down staged. On analysis of stage III/Iv and recurrent melanoma, a change in stage occurred in 90% of stage III, 50% of stage IV and 50% of recurrent melanoma patients. This effected a change in management in 86.7% of patients with stage III, IV and recurrent melanoma collectively CONCLUSION: PET-CT is a useful tool in the staging and subsequent management of melanoma. Its utility is pronounced in advanced and recurrent melanomaen_ZA
dc.description.versionPublisher's version
dc.format.extent6 pages
dc.identifier.citationTwycross, S. H., Burger, H. & Holness, J. 2019. The utility of PET-CT in the staging and management of advanced and recurrent malignant melanoma. South African Journal of Surgery, 57(3):44-49, doi:10.17159/2078-5151/2019/v57n3a2832.
dc.identifier.issn2078-5151 (online)
dc.identifier.issn0038-2361 (print)
dc.identifier.otherdoi:10.17159/2078-5151/2019/v57n3a2832
dc.identifier.urihttp://hdl.handle.net/10019.1/110656
dc.language.isoen_ZAen_ZA
dc.publisherMedpharm Publications
dc.rights.holderAuthors retain copyright
dc.subjectMelanomaen_ZA
dc.subjectSkin -- Cancer -- Diagnosisen_ZA
dc.subjectSkin -- Tomographyen_ZA
dc.subjectTomography, Emissionen_ZA
dc.titleThe utility of PET-CT in the staging and management of advanced and recurrent malignant melanomaen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
twycross_utility_2019.pdf
Size:
283.28 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Radiation Oncology)